Paul Matteis
PersonHeard in 1 episode across 1 show since Oct 2026
Paul Matteis is a managing director and head of therapeutics research at Stifel. He is known for his analysis and coverage of biotechnology companies and therapeutics development.
Episodes
First heard
Guest appearances
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Nov 2025 | 0 |
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 0 |
| Oct 2026 | 1 |
Email alert
Email me when Paul Matteis comes up on a podcast
One email a week at most, with the new episodes that mention Paul Matteis. Free, no account needed, unsubscribe in one click.
What Paul Matteis has said on podcasts
8 statements
Biotech market conditions are now strongly behavioral and psychological.
“I think we're in like the inning of this market now where it's become just as much behavioral and psychological as really anything else.”
Open the episode · Episode 199 - October 16, 2026Listen at 10:38
Investors cannot determine when the biotech selloff will end.
“no one really knows when this carnage is going to stop.”
Open the episode · Episode 199 - October 16, 2026Listen at 11:08
A string of biotech M&A could help end the sector’s bear market.
“if we do start to see a string of M&A, I do feel like, you know, I feel like it's the cliche all the time to say that M&A. kind of cures bear markets in biotech”
Open the episode · Episode 199 - October 16, 2026Listen at 11:38
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
1 episode featuring Paul Matteis, newest first
